Patrys Limited Announces Successful Phase I Clinical Trial for PAT-SM6

Published: Mar 20, 2012

Melbourne, Australia; 20 March, 2012: Patrys Limited (ASX: PAB; “the Company”), a clinical stage biopharmaceutical company, is pleased to advise that final data is now available from its recently completed Phase I clinical trial. This trial was conducted in patients with melanoma, who were dosed with the Company’s anti-tumour antibody PAT-SM6. The data provides uniform evidence for PAT-SM6’s safety, and initial data supporting its ability to specifically target melanoma tumours.

The primary trial objective was to establish safety and tolerability. No significant safety issues were observed or reported for any patients treated with PAT-SM6 during infusion, immediately following dosing, or during the month-long follow up period. All patients completed the trial without incident and were eligible for assessment.

There were a number of additional secondary objectives. Analysis of blood samples collected during the trial confirmed that no patient generated a significant adverse immune response to PAT-SM6. This is an important finding as adverse immune reactions to existing marketed antibodies is known to limit the effectiveness of these treatments. This result provides additional support for the Company’s decision to ensure the natural human properties of the antibodies are preserved throughout development, by advancing production through the manufacturing human cell line PER.C6®.

Additional blood samples were assessed for pharmacokinetic parameters (such as drug half-life) to provide valuable information which will aid in the design of dosing regimens for the next PAT-SM6 trial currently in planning, with patients suffering from multiple myeloma, a serious blood cancer.

Pre-dose and post-dose melanoma tumour samples from the final cohort were also examined. Despite the low dose of PAT-SM6 relative to expected therapeutic dose levels, an increased level of cancer cell death (apoptosis) was observed to be widespread in one of the patient’s post-treatment samples, compared to the same patient’s pre-treatment specimen.

“This data is very exciting and provides a glimpse into the promise of Patrys’ unique pipeline which is based on natural human antibodies like PAT-SM6. The safety of PAT-SM6 as demonstrated in this trial and the additional information we have gathered lays the groundwork for our upcoming multidose study in patients with multiple myeloma,” said Dr Marie Roskrow, Patrys’ Chief Executive Officer.

“These data represent a significant milestone for Patrys and strengthens our position as a clinical stage cancer development company.”

In addition to the completion of the clinical trial, Patrys has recently completed an additional multi-dose animal toxicology study in order to further support human trials and the pool of data surrounding PAT-SM6. No adverse effects were observed in the test animals despite the very high doses administered. These doses were many times the expected maximum therapeutic dose that would be used to treat humans, and therefore create a significant safety margin for dosing in future trials.

PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer including solid tumours (e.g. melanoma), and multiple myeloma. It is the first reported clinical product to target an important protein on the surface of cancer cells called GRP78 that plays a number of key roles in cancer cell survival, growth and metastasis.

Back to news